Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Drug Discov Today ; 27(1): 65-81, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-34461236

RESUMEN

Biological drugs or biopharmaceuticals off patent open a large market for biosimilars and biobetters, follow-on biologics. Biobetters, in particular, are new drugs designed from existing ones with improved properties such as higher selectivity, stability, half-life and/or lower toxicity/immunogenicity. Glycosylation is one of the most used strategies to improve biological drugs, nonetheless bioconjugation is an additional alternative and refers to the covalent attachment of polymers to biological drugs. Extensive research on novel polymers is underway, nonetheless PEGylation is still the best alternative with the longest clinical track record. Innovative trends based on genetic engineering techniques such as fusion proteins and PASylation are also promising. In this review, all these alternatives wereexplored as well as current market trends, legislation and future perspectives.


Asunto(s)
Productos Biológicos , Biosimilares Farmacéuticos , Productos Biológicos/farmacología , Productos Biológicos/normas , Biosimilares Farmacéuticos/farmacología , Biosimilares Farmacéuticos/normas , Quimioterapia/tendencias , Humanos , Ingeniería Metabólica/métodos , Ingeniería de Proteínas/métodos , Mejoramiento de la Calidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA